Abstract Number: 056 • 2023 Pediatric Rheumatology Symposium
An Advanced Physiotherapist Practitioner Model of Care Is Ideally Suited to Address Workforce Concerns in Pediatric Rheumatology: A Retrospective Chart Review
Background/Purpose: An Advanced Physiotherapist Practitioner (APP) role was created in September 2020 at McMaster Children's Hospital, Ontario, Canada to support the growing demand for service…Abstract Number: 093 • 2023 Pediatric Rheumatology Symposium
Comparison Between Induction with Rituximab and Cyclophosphamide in Treatment of Childhood-Onset ANCA-Associated Vasculitis
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are a group vasculitides with significant morbidity and mortality requiring toxic therapy. Clinical trials in adults…Abstract Number: 137 • 2023 Pediatric Rheumatology Symposium
Geographic Mapping of Adolescents with Rheumatic Disease: Racial and Ethnic Diversity by Texas County
Background/Purpose: Rheumatic disease disproportionately impacts specific racial and ethnic groups frequently, resulting in health care inequities. Health care disparities are prevalent within certain geographic areas…Abstract Number: 021 • 2023 Pediatric Rheumatology Symposium
Distinguishing Childhood Sjogren’s Disease in Patients Presenting with Recurrent Sialadenitis in a Multidisciplinary Clinic
Background/Purpose: Sialadenitis is a common distinguishing manifestation of Childhood Sjogrens Disease (cSD). We have previously reported a surprisingly high rate of Childhood Sjogrens Disease (cSD)…Abstract Number: 058 • 2023 Pediatric Rheumatology Symposium
High Levels of Psychological Distress, Depression, and Anxiety Symptoms in Children with Pediatric Rheumatologic Diseases
Background/Purpose: Mental health problems are common in children with pediatric rheumatologic diseases (PRDs) and are associated with worsened quality of life and poorer disease-related outcomes.…Abstract Number: 099 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Juvenile Dermatomyositis
Background/Purpose: Juvenile Dermatomyositis (JDM) is theorized to occur in a genetically susceptible individual as a response to an environmental trigger, leading to autoimmunity and inflammation.…Abstract Number: 016 • 2023 Pediatric Rheumatology Symposium
Gene Expression Changes in Polyarticular Juvenile Idiopathic Arthritis Following Tofacitinib Treatment
Background/Purpose: Despite advances in the understanding of juvenile idiopathic arthritis (JIA) pathophysiology, personalized treatments informed by gene transcriptomic profiles remain elusive. We aimed toexamine the…Abstract Number: 059 • 2023 Pediatric Rheumatology Symposium
Update of Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem. Despite recent advances, there remain key unanswered questions…Abstract Number: 102 • 2023 Pediatric Rheumatology Symposium
Preliminary Results from a Survey of Psychological Resilience Among JIA Patients
Background/Purpose: Psychological resilience – an individuals capacity to adapt in the face of stressors and recover after adverse events – has been linked to a…Abstract Number: 015 • 2023 Pediatric Rheumatology Symposium
Epigenetically-Distinct B Cell Profiles Pre- and Post-Induction Therapy in Pediatric Lupus
Background/Purpose: Systemic lupus erythematosus (SLE) may be triggered by gene-environment interactions. Data are scarce on how epigenetic variance contributes to disease risk in pediatric SLE…Abstract Number: 061 • 2023 Pediatric Rheumatology Symposium
Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in children in North America. Initial treatment with IVIG has significantly reduced the…Abstract Number: 103 • 2023 Pediatric Rheumatology Symposium
Clinical, Serologic, and Imaging Findings of Rhupus Syndrome in the Pediatric Population: A Systematic Literature Review
Background/Purpose: Pediatric Rhupus syndrome is a complex autoimmune disease characterized by overlapping clinical and immunological features of Juvenile Idiopathic Arthritis (JIA) and juvenile Systemic Lupus…Abstract Number: 011 • 2023 Pediatric Rheumatology Symposium
The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center
Background/Purpose: Differences in prevalence rates of childhood-onset SLE (cSLE) among different racial/ethnic groups have been well described. Yet, the role of social determinants of health…Abstract Number: 062 • 2023 Pediatric Rheumatology Symposium
Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
Background/Purpose: Since 2010, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) has developed 12 consensus treatment plans (CTP) with the aim of reducing treatment variability…Abstract Number: 106 • 2023 Pediatric Rheumatology Symposium
Caregivers’ Perspectives on Barriers to Care in Juvenile Localized and Systemic Scleroderma
Background/Purpose: Juvenile localized scleroderma (LS) and systemic sclerosis (SSc) are rare rheumatic diseases often associated with severe morbidities. Delays in diagnosis are common, putting children…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 41
- Next Page »